Literature DB >> 22188562

Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue.

Sarah Tzu-Feng Hsiao1, Azar Asgari, Zerina Lokmic, Rodney Sinclair, Gregory James Dusting, Shiang Yong Lim, Rodney James Dilley.   

Abstract

Human adult mesenchymal stem cells (MSCs) support the engineering of functional tissue constructs by secreting angiogenic and cytoprotective factors, which act in a paracrine fashion to influence cell survival and vascularization. MSCs have been isolated from many different tissue sources, but little is known about how paracrine factor secretion varies between different MSC populations. We evaluated paracrine factor expression patterns in MSCs isolated from adipose tissue (ASCs), bone marrow (BMSCs), and dermal tissues [dermal sheath cells (DSCs) and dermal papilla cells (DPCs)]. Specifically, mRNA expression analysis identified insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor-D (VEGF-D), and interleukin-8 (IL-8) to be expressed at higher levels in ASCs compared with other MSC populations whereas VEGF-A, angiogenin, basic fibroblast growth factor (bFGF), and nerve growth factor (NGF) were expressed at comparable levels among the MSC populations examined. Analysis of conditioned media (CM) protein confirmed the comparable level of angiogenin and VEGF-A secretion in all MSC populations and showed that DSCs and DPCs produced significantly higher concentrations of leptin. Functional assays examining in vitro angiogenic paracrine activity showed that incubation of endothelial cells in ASC(CM) resulted in increased tubulogenic efficiency compared with that observed in DPC(CM). Using neutralizing antibodies we concluded that VEGF-A and VEGF-D were 2 of the major growth factors secreted by ASCs that supported endothelial tubulogenesis. The variation in paracrine factors of different MSC populations contributes to different levels of angiogenic activity and ASCs maybe preferred over other MSC populations for augmenting therapeutic approaches dependent upon angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22188562      PMCID: PMC3411362          DOI: 10.1089/scd.2011.0674

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  70 in total

1.  Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells.

Authors:  Bénédicte Puissant; Corinne Barreau; Philippe Bourin; Cyril Clavel; Jill Corre; Christine Bousquet; Christine Taureau; Béatrice Cousin; Michel Abbal; Patrick Laharrague; Luc Penicaud; Louis Casteilla; Antoine Blancher
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

2.  Leptin and leptin receptor mRNA and protein expression in the murine fetus and placenta.

Authors:  N Hoggard; L Hunter; J S Duncan; L M Williams; P Trayhurn; J G Mercer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

3.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

4.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).

Authors:  M G Achen; M Jeltsch; E Kukk; T Mäkinen; A Vitali; A F Wilks; K Alitalo; S A Stacker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

5.  Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.

Authors:  Matus Studeny; Frank C Marini; Jennifer L Dembinski; Claudia Zompetta; Maria Cabreira-Hansen; Benjamin Nebiyou Bekele; Richard E Champlin; Michael Andreeff
Journal:  J Natl Cancer Inst       Date:  2004-11-03       Impact factor: 13.506

6.  Vascular endothelial growth factor D is dispensable for development of the lymphatic system.

Authors:  Megan E Baldwin; Michael M Halford; Sally Roufail; Richard A Williams; Margaret L Hibbs; Dianne Grail; Hajime Kubo; Steven A Stacker; Marc G Achen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells.

Authors:  J U Yoo; T S Barthel; K Nishimura; L Solchaga; A I Caplan; V M Goldberg; B Johnstone
Journal:  J Bone Joint Surg Am       Date:  1998-12       Impact factor: 5.284

8.  Leptin regulation of peroxisome proliferator-activated receptor-gamma, tumor necrosis factor, and uncoupling protein-2 expression in adipose tissues.

Authors:  H Qian; G J Hausman; M M Compton; M J Azain; D L Hartzell; C A Baile
Journal:  Biochem Biophys Res Commun       Date:  1998-05-29       Impact factor: 3.575

9.  Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure.

Authors:  Lili Li; Shuo Zhang; Yao Zhang; Bo Yu; Yan Xu; Zhenzhong Guan
Journal:  Mol Biol Rep       Date:  2008-03-27       Impact factor: 2.316

10.  Mesenchymal stem cells genetically modified with the angiopoietin-1 gene enhanced arteriogenesis in a porcine model of chronic myocardial ischaemia.

Authors:  S L Chen; C C Zhu; Y Q Liu; L J Tang; L Yi; B J Yu; D J Wang
Journal:  J Int Med Res       Date:  2009 Jan-Feb       Impact factor: 1.671

View more
  137 in total

Review 1.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors:  Johan Kreuger; Mia Phillipson
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

2.  Dynamic secretome of bone marrow-derived stromal cells reveals a cardioprotective biochemical cocktail.

Authors:  David D Ellison; Yasir Suhail; Junaid Afzal; Laura Woo; Onur Kilic; Jeffrey Spees; Andre Levchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-25       Impact factor: 11.205

3.  A comparative study on the transplantation of different concentrations of human umbilical mesenchymal cells into diabetic rats.

Authors:  Jia-Hui Kong; Dan Zheng; Song Chen; Hong-Tao Duan; Yue-Xin Wang; Meng Dong; Jian Song
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

4.  Efficient and sustained IGF-1 expression in the adipose tissue-derived stem cells mediated via a lentiviral vector.

Authors:  Ting Chen; Dangsheng Huang; Guanghui Chen; Tingshu Yang; Jun Yi; Miao Tian
Journal:  J Mol Histol       Date:  2014-12-03       Impact factor: 2.611

Review 5.  Emergence of the Stem Cell Secretome in Regenerative Engineering.

Authors:  Leila Daneshmandi; Shiv Shah; Tahereh Jafari; Maumita Bhattacharjee; Deandra Momah; Nikoo Saveh-Shemshaki; Kevin W-H Lo; Cato T Laurencin
Journal:  Trends Biotechnol       Date:  2020-07-01       Impact factor: 19.536

Review 6.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

7.  Mesenchymal Stem/Stromal Cells in Regenerative Medicine: Can Preconditioning Strategies Improve Therapeutic Efficacy?

Authors:  Richard Schäfer; Gabriele Spohn; Patrick C Baer
Journal:  Transfus Med Hemother       Date:  2016-07-20       Impact factor: 3.747

Review 8.  Stem Cell Sources and Graft Material for Vascular Tissue Engineering.

Authors:  Dorothee Hielscher; Constanze Kaebisch; Benedikt Julius Valentin Braun; Kevin Gray; Edda Tobiasch
Journal:  Stem Cell Rev Rep       Date:  2018-10       Impact factor: 5.739

9.  Emulating native periosteum cell population and subsequent paracrine factor production to promote tissue engineered periosteum-mediated allograft healing.

Authors:  Michael D Hoffman; Danielle S W Benoit
Journal:  Biomaterials       Date:  2015-03-18       Impact factor: 12.479

10.  Adipose-derived stem cells (ADSCs) and muscle precursor cells (MPCs) for the treatment of bladder voiding dysfunction.

Authors:  Mathias Tremp; Souzan Salemi; Remo Largo; Karl-Erik Andersson; Jan A Plock; Jan Plock; Tamer Aboushwareb; Tullio Sulser; Daniel Eberli
Journal:  World J Urol       Date:  2013-11-12       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.